Need for a simpler method for ICP measurement
Several neurological conditions are associated with raised intracranial pressure. Traumatic Brain Injury alone affects nearly 70 million people each year worldwide. Today ICP is measured invasively by inserting a pressure sensor through a cranial burr hole. The invasive procedure is performed by highly specialized personnel and carries along a high cost and risk of infection and bleeding. Early diagnostics and treatment is important. Nisonic has developed the technology to enable non-invasive detection of increased intracranial pressure.
Dr. Llewellyn Padayachy introducing Nisonic’s non-invasive method to detect increased intracranial pressure using ultrasound
Ultrasound imaging for non-invasive detection of ICP
Nisonic has developed a novel method for measuring the static and dynamic properties of the optic nerve sheath to detect the patient’s intracranial pressure. The method has been developed by engineers at SINTEF, Trondheim, Norway and neurosurgeons at Red Cross War Memorial Children’s Hospital, University of Cape Town in South Africa. The ultrasound system consists of a dedicated probe for transorbital ultrasound imaging together with advanced machine learning algorithms for automatic measurements and guiding.
Fast and simple
A few minutes per eye
No equipment calibration
Easy to use
Guided probe positioning
Better patient care
Enables earlier treatment
Reduced invasive interventions
Nisonic AS is a medical device company developing products for non-invasive detection of intracranial pressure (ICP) using ultrasound imaging and machine learning. The company was established in 2017 in Trondheim, Norway, and is a spin-out from SINTEF Medical Technology. Ultrasound experts and neurosurgeons have been working together since 2013 combining world leading ultrasound technology with clinical expertise to develop the new method for detecting intracranial pressure.
Research & concept
Concept developed by neurosurgeons and researchers in Norway and South Africa
Product design/Proof of concept
Clinical studies / 2 publications
Pulsatile Dynamics of the Optic Nerve Sheath and Intracranial Pressure: An Exploratory In Vivo Investigation
Noninvasive Transorbital Assessment of the Optic Nerve Sheath in Children: Relationship Between Optic Nerve Sheath Diameter, Deformability Index, and Intracranial Pressure
Patent application filed
Dedicated transducer design
Technology and product improvements
1st CE marked system
- Optimized transducer for transorbital ultrasound imaging
- Automatic measurements based on advanced machine-learning algorithms
- Guidance for accurate probe positioning
The Nisonic system will be available in a limited number at the end of 2019 for university hospitals doing research on ICP. We continue developing the system, and partners will be invited to our R&D program.Contact us
Cornelia has a broad leadership experience from global high-tech companies like GE Healthcare, Kongsberg Group, and Telenor within the areas of R&D, manufacturing, business development and commercializing new products and services. Prior to Nisonic Cornelia held the position as CEO of Novelda AS, a world leading sensor technology company. Her broad international experience includes negotiations with strategic partners and customers. Cornelia has a MSc degree in Industrial economics and technology management from Norwegian University of Science and Technology (NTNU).
Tormod has more than 17 years’ experience working with research and development of medical technology and medical devices within ultrasound imaging and data processing. Tormod has be involved from the start of several R&D projects to the commercial stage with establishment of companies. Prior to Nisonic he worked as Research Manager at the Medical Technology Group at SINTEF and as Research Geophysicist in PGS. Tormod Selbekk has a MSc in electrical engineering (acoustics) and holds a PhD in Medical technology from Norwegian University of Science and Technology (NTNU)
Heidi is a medical doctor with several years of clinical experience, mainly from Oslo University Hospital (OUS). She has broad experience, primarily working at the neonatal intensive care unit with particular interest in circulation, pediatric cardiology and research. The last decade before joining Nisonic, Heidi held different leadership positions in big pharma at Nordic and national level as Medical Director – accountable for medical affairs, pharmacovigilance, medical information and clinical studies.
Heidi has her medical degree from Norwegian University of Science and Technology (NTNU) and is a specialist in pediatrics.
Dag Marius Brurok
Dag has worked as a nurse at St. Olav’s hospital in Trondheim for 9 years and of which the last 5 years at the neuro-intensive care unit, before joining Nisonic in 2019. He has expertise in measuring and treating high intracranial pressure in critically ill patients. In addition, he has experience in measuring vascular spasms using doppler ultrasound in patients with subarachnoid bleeding. Dag holds a bachelor degree in Nursing (BSN) from Høgskolen i Nord-Trøndelag in Norway.
Roar has more than 30 years of experience in industrial software development for maritime and industrial environments. Key competences are within machine vision, data acquisition, image processing and logging, industrial camera interfacing, generic I/O and communication, system integration and user interfaces. Prior to Nisonic, Roar worked as software developer of Tordivel AS Scorpion Vision Software. Roar holds a BSc degree in Electrical, Electronics and Communications Engineering from Trondheim Ingeniørhøgskole in Norway.
Vidar has more than 20 years experience in software development, mainly within medical ultrasound technology. Vidar was responsible for developing image acquisition and analysis software for Stress Echocardiography in GE Vingmed Ultrasound, including patented new methodologies. His experience also includes software development within 3D graphics in Ceetron AS and developing software for programming and debugging microcontrollers in Atmel / Microchip Technology. Vidar has a MSc degree in Computer Science from Norwegian University of Science and Technology (NTNU) in Norway.
We are an interdisciplinary and experienced team in the intersection of technology and healthcare.
With leading competence within ultrasound technology we are collaborating closely with international neurosurgeons, clinicians and research institutes to enable better diagnostics and treatment.
Would you like to join our team?
Please send your CV and motivation to email@example.com
SINTEF TTO & Venture
Inge has more than 16 years of experience from all aspects of leading, building and investing in companies with innovative and disruptive technologies. Inge currently works as Investment Director for Sintef TTO and as Board member at Ocean Space Acoustics, Nisonic, Sensibel, Tellu, BrainImage. Earlier he was COO at Petrosreamz , CEO at MemfoACT, Board member at Robotic Drilling Systems, Exprosoft, Investinor, Pinovo, and Manager for Nanotechnology at NTNU. MSc in Materials Science from NTNU and Executive Certificate in Strategy & Innovation from MIT Sloan School of Management.
Ingrid Teigland Akay
Ingrid is a medical doctor and investment professional with background in healthcare, consumer goods and technology. She is founder and managing partner of Hadean Ventures, a European life science fund manager. Prior to starting Hadean Ventures, Ingrid served as a senior investment professional at London-based Inventages. As a medical doctor, Ingrid worked within general medicine and surgery, with exposure to both the public and private sector. Ingrid holds a medical degree from Medizinische Hochschule Hannover, Germany, and an MBA with Finance Concentration from London Business School.
Øivind holds a PhD in microbiology and has more than 13 years of research experience in molecular microbiology, microbial ecology and fish disease, and 7 years in commercializing research-based projects in biology, aqua culture, medicine and biotechnology. He has several years of managerial and board experience from position with Sarsia Innovation AS and Sarsia Seed Management AS.
Our advisory board
Steve Biko Academic Hospital
Llewellyn (Chairman of SAB) is a neurosurgeon, currently serving as professor and head at the University of Pretoria, Steve Biko Academic Hospital, Pretoria, South Africa. He is primarily a pediatric neurosurgeon with special interests in non-invasive diagnostic and minimally invasive surgical techniques and serves on the executive committees various international and local neurosurgical organisations. He has over a decade developed novel non-invasive diagnostic methods using ultrasound-based parameters for detection of ICP.
MD, University of Bergen in 1985. PhD, University of Trondheim 1988. Postdoc at Dana Farber Cancer Institute, Harvard University in Boston 1988/1989. Board certified Neurosurgeon in 1996. Appointed professor in Neurosurgery, University of Oslo in 2004. Professor Helseth is an experienced neurosurgeon and researcher with special interest in brain tumors and neurotrauma.
Stephan A. Mayer
Professor of Neurology Wayne State University
Stephan A. Mayer became Chair of Neurology for the Henry Ford Health System in Detroit, Michigan in 2017. Prior to that Dr. Mayer was Director of Neurocritical Care for the Mount Sinai Health System in New York, and before that, Director of the Neuro-ICU and Professor of Neurology and Neurological Surgery at Columbia University. His research interest includes Subarachnoid haemorrhage, Intracerebral haemorrhage and Brain multi-modality monitoring.
Professor in Neurology & Former Chief of Neurovascular Division at Weill-Cornell Medical College. Founder, Chair, and CEO of several med-tech and biotech companies. Denise received her Medical Degree from University College Hospital, UK and completed her neurologic training at Weill-Cornell Medical Center and Memorial Sloan-Kettering Cancer Center. Subsequently she became an Attending Physician at New York Hospital and Professor of Neurology at Cornell University. Denise is sole or lead author on close to 200 issued or pending patents, and has been involved in founding, funding and running bio- and med-tech companies for 20 years.